USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
REGENEREX, LLC
Address:
201 E JEFFERSON ST
LOUISVILLE, KY 40202-
Phone:
N/A
URL:
N/A
EIN:
300093189
DUNS:
140644969
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
STTR Phase I $1,323,163.00 4
STTR Phase II $5,015,114.00 2

Award List:

Stem Cell Graft Engineering to Treat Sickle Cell Disease

Award Year / Program / Phase:
2004 / STTR / Phase I
Award Amount:
$220,500.00
Agency:
HHS
Principal Investigator:
Research Institution:
UNIVERSITY OF LOUISVILLE
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is an abnormality of red blood cells (RBC) that affects approximately 72,000 people in the United States, or approximately 1 in every 500 African-Americans. With current therapies, the mortality in the United States is 50 percent by age… More

Stem Cell Graft Engineering to Treat Sickle Cell Disease

Award Year / Program / Phase:
2008 / STTR / Phase II
Award Amount:
$1,414,979.00
Agency:
HHS
Principal Investigator:
Research Institution:
N/A
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): Sickle Cell Disease (SCD) is a genetic abnormality of red blood cells (RBC) that affects over 70,000 people in the United States, or approximately 1 in every 500 African-Americans. With current therapies, the mortality in the United States is 50% by age 40. SCD… More

Induction of Donor Tolerance in Renal Transplants

Award Year / Program / Phase:
2011 / STTR / Phase II
Award Amount:
$3,600,135.00
Agency:
HHS
Principal Investigator:
Suzanne T. Ildstad – 502-852-2080
Research Institution:
UNIVERSITY OF LOUISVILLE
RI Contact:
Abstract:
DESCRIPTION: Renal transplantation is the preferred therapeutic approach for end organ failure. However, the chronic use of immunosuppressive agents is critical to prevent rejection. The drugs are costly ( 15,000-25,000/year) and have significant toxicities including opportunistic infection, an… More

Delayed Tolerance Induction in Living Related Donor Renal Transplant Recipients

Award Year / Program / Phase:
2012 / STTR / Phase I
Award Amount:
$299,662.00
Agency:
HHS
Principal Investigator:
Suzanne T. Ildstad – 502-852-2080
Research Institution:
UNIVERSITY OF LOUISVILLE
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): We have developed a protocol that reproducibly induces transplantation tolerance in individuals undergoing a living related donor kidney transplant. Three subjects have been off all immunosuppression for 10 months, 2 months, and 1 month respectively and have… More